⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5248943 | 1.00 | — | — | |
| SCHEMBL8116115 | 0.83 | — | — | |
| SCHEMBL8865924 | 0.78 | — | — | |
| SCHEMBL1042812 | 0.76 | — | — | |
| SCHEMBL30675167 | 0.74 | — | — | |
| SCHEMBL4788208 | 0.74 | — | — | |
| SCHEMBL40708 | 0.74 | — | — | |
| SCHEMBL30532723 | 0.74 | — | — | |
| SCHEMBL26969254 | 0.74 | — | — | |
| Hydrochloric Acid SCHEMBL29508586 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250059151-A1 | GRISEOFULVIN COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-02-20 | — | — | US | disclosed |
| US-12091395-B2 | Griseofulvin compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2024-09-17 | — | — | US | disclosed |
| US-20240239778-A1 | GRISEOFULVIN COMPOUND AND PHARMACEUTICAL USE THEREOF | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2024-07-18 | — | — | US | disclosed |
| US-11993593-B2 | Griseofulvin compound and pharmaceutical use thereof | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2024-05-28 | — | — | US | disclosed |
| US-20240150309-A1 | GRISEOFULVIN COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2024-05-09 | — | — | US | disclosed |
| US-11834427-B2 | Griseofulvin compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-12-05 | — | — | US | disclosed |
| US-20230136988-A1 | GRISEOFULVIN COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-05-04 | — | — | US | disclosed |
| US-20220411416-A1 | GRISEOFULVIN COMPOUND AND PHARMACEUTICAL USE THEREOF | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-12-29 | — | — | US | disclosed |
| US-11472784-B2 | Griseofulvin compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-10-18 | — | — | US | disclosed |
| US-11407746-B2 | Griseofulvin compound and pharmaceutical use thereof | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-08-09 | — | — | US | disclosed |
| US-20200216433-A1 | GRISEOFULVIN COMPOUND AND PHARMACEUTICAL USE THEREOF | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2020-07-09 | — | — | US | disclosed |
| US-10654821-B2 | Griseofulvin compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2020-05-19 | — | — | US | disclosed |
| US-10570109-B2 | Griseofulvin compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2020-02-25 | — | — | US | disclosed |
| US-20190092741-A1 | GRISEOFULVIN COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2019-03-28 | — | — | US | disclosed |
| EP-3438103-A1 | GRISEOFULVIN COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2019-02-06 | — | — | EP | disclosed |
| US-8470829-B2 | Imidazolidine derivative and use thereof | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2013-06-25 | — | — | US | disclosed |
| US-20110306615-A1 | NOVEL IMIDAZOLIDINE DERIVATIVE AND USE THEREOF | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-12-15 | — | — | US | disclosed |
| EP-1790640-A1 | NOVEL IMIDAZOLIDINE DERIVATIVE AND USE THEREOF | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-05-30 | — | — | EP | disclosed |
| US-20060089353-A1 | Indole derivative compounds and drugs containing the compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-04-27 | — | — | US | disclosed |
| EP-1600440-A1 | INDOLE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-11-30 | — | — | EP | disclosed |